Structure of the PPARα and -γ Ligand Binding Domain in Complex with AZ 242; Ligand Selectivity and Agonist Activation in the PPAR Family  by Cronet, Philippe et al.
Structure, Vol. 9, 699–706, August, 2001, 2001 Elsevier Science Ltd. All rights reserved. PII S0969-2126(01)00634-7
Structure of the PPAR and - Ligand Binding
Domain in Complex with AZ 242; Ligand Selectivity
and Agonist Activation in the PPAR Family
man health, leading to obesity, cardiovascular diseases,
insulin resistance, type II diabetes, and atherosclerosis.
Several nuclear receptors, including the peroxisome
proliferator-activated receptors (PPARs), control the ex-
pression of genes involved in fatty acid metabolism.
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2 Structural Chemistry Laboratory Three subtypes of PPARs have been identified: ,  (or
, Nuc-1), and , each with specific roles and tissue3 Department of Medicinal Chemistry
AstraZeneca R&D Mo¨lndal distribution [1]. In general, PPAR promotes fatty acid
catabolism in the liver and skeletal muscle, while PPARS-431 83 Mo¨lndal
Sweden regulates fatty acid storage in adipose tissues. The
physiological role of PPAR is poorly understood, but
a direct link between PPAR and embryo implantation
in the mouse and apoptosis of colon tumor cells hasSummary
been demonstrated [2, 3]. Similar to the other subtypes,
PPAR binds fatty acids and eicosanoids, suggestingBackground: The peroxisome proliferator-activated re-
ceptors (PPAR) are ligand-activated transcription fac- that it is involved in lipid metabolism (see [4] for a recent
review). Both PPAR and PPAR have been demon-tors belonging to the nuclear receptor family. The roles
of PPAR in fatty acid oxidation and PPAR in adipocyte strated to be targets for several antidyslipidemic phar-
macological agents. Among them, fibrates have beendifferentiation and lipid storage have been characterized
extensively. PPARs are activated by fatty acids and ei- used since the 1960s to lower hypertriglyceridemia and
were recently shown to be weak PPAR agonists [5].cosanoids and are also targets for antidyslipidemic
drugs, but the molecular interactions governing ligand PPAR is activated by several compounds, including
the thiazolidinediones (TZDs) [6], a class of compoundsselectivity for specific subtypes are unclear due to the
lack of a PPAR ligand binding domain structure. used clinically as insulin sensitizers [7] to lower blood
glucose in patients with type II diabetes. Both fibrates
and TZDs have been shown to lower circulating triglyc-Results: We have solved the crystal structure of the
PPAR ligand binding domain (LBD) in complex with erides in animal models of hypertriglyceridemia [8].
The structures of the ligand binding domains of humanthe combined PPAR and - agonist AZ 242, a novel
dihydro cinnamate derivative that is structurally different PPAR [9–11] and human PPAR [12] have recently been
solved in complex with several ligands, providing afrom thiazolidinediones. In addition, we present the
crystal structure of the PPAR_LBD/AZ 242 complex structural basis for agonist activation of these subtypes
in which the ligand hydrophilic head group plays a keyand provide a rationale for ligand selectivity toward the
PPAR and - subtypes. Heteronuclear NMR data on role. However, the general relevance of the activation
process remains an open question in the absence of anPPAR in both the apo form and in complex with AZ 242
shows an overall stabilization of the LBD upon agonist agonist-bound PPAR_LBD structure. Molecular insight
into the interaction of PPAR with a ligand will facilitatebinding. A comparison of the novel PPAR/AZ 242 com-
plex with the PPAR/AZ 242 complex and previously the rational design of selective PPAR modulators, which
are likely to improve current antidyslipidemic agents.solved PPAR structures reveals a conserved hydrogen
bonding network between agonists and the AF2 helix. We present the X-ray structure of the ligand binding
domain of human PPAR (here denoted hPPAR_LBD)
in complex with AZ 242, a novel compound with com-Conclusions: The complex of PPAR and PPAR with
the dual specificity agonist AZ 242 highlights the con- bined PPAR and - agonist activity that is structurally
different than thiazolidinediones. We also report on theserved interactions required for receptor activation. To-
gether with the NMR data, this suggests a general model conformational differences induced by AZ 242 binding
to hPPAR_LBD, as observed by NMR. Based on thesefor ligand activation in the PPAR family. A comparison
of the ligand binding sites reveals a molecular explana- data, we propose a general mechanism of ligand-depen-
dent activation that is common to the entire PPAR family,tion for subtype selectivity and provides a basis for ratio-
nal drug design. and we provide a molecular explanation for drug selec-
tivity toward the two PPAR subtypes.
Introduction
Results and Discussion
Fatty acids are key components of several metabolic
pathways, and organisms have evolved complex mech- Activation of PPAR and PPAR Ligand Binding
Domains by AZ 242anisms to maintain a proper balance between absorp-
tion, secretion, consumption, and storage of fatty acids. AZ 242 is a dihydro cinnamate derivative under develop-
ment for treatment of insulin resistance-related glucoseDisorders of lipid metabolism are a major threat to hu-
4 Correspondence: krister.bamberg@astrazeneca.com Key words: PPAR; agonist; ligand binding domain; structure; NMR;
activation5 These authors contributed equally to the work.
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Figure 1. Competition Binding and Coactiva-
tor Recruitment of AZ 242
(a) PPAR (solid squares)- or PPAR (open
squares)-bound 3H-AR-H040156 (racemate
of AZ 242) was displaced by adding increas-
ing amounts of AZ 242. IC50 values for AZ 242
in PPAR and PPAR were 1.0 M and 0.2
M, respectively. The inset figure shows that
scintillation from the SPA beads is dependent
on the presence of a specific receptor, since
the addition of RNaseH to the beads did not
increase the counts over background.
(b) AZ 242-mediated coactivator recruitment
of SRC-1 peptide to PPAR (solid squares)
or PPAR (open squares) was determined in
an in vitro assay based on homogenous time-
resolved fluorescence. EC50 values for AZ 242
in PPAR and PPAR were 1.2 M and 1.3
M, respectively. The AZ 242 structure is il-
lustrated between the diagrams. XLfit (ID
Business Solutions) was used to perform
curve fitting and IC50/EC50 calculations.
and lipid abnormalities associated with type II diabetes General Structural Features
The structure of hPPAR_LBD was solved by molecularand insulin resistance syndrome. A scintillation proxim-
ity assay (SPA) was used to determine the binding affini- replacement and refined including all diffraction data to
2.2 A˚ (Table 1). The final model consists of oneties of AZ 242 toward hPPAR and mPPAR (Figure 1a).
Both receptors bind to the scintillant containing SPA hPPAR_LBD molecule per asymmetric unit. The ago-
nist, AZ 242, the steroid part of a detergent (Deoxy-BIG-beads by electrostatic interaction, and the dissociation
of tritiated AR-H040156 (racemate of AZ 242) is mea- CHAP [DBC]), and 71 water molecules were included in
the final model.sured at equilibrium without the need for the separation
of bound/unbound material. AZ 242 displaces PPAR- The overall structure of hPPAR_LBD encompasses
residues 199–468. Most residues are placed in well-and --bound 3H-AR-H040156 with IC50 values of 1.0 M
and 0.2 M, respectively. To demonstrate the agonist defined electron density, except for two regions, resi-
dues 232–234 and residues 254–264, for which no inter-nature of AZ 242 on both PPAR and PPAR, we tested
AZ 242 in coactivator recruitment assays based on ho- pretable densities were obtained. Both regions have
been left out of the model (Figure 2a). An example ofmogenous time-resolved fluorescence (Figure 1b).
AZ 242 led to the recruitment of SRC-1 to both PPAR an Fo-Fc electron density omit map calculated around
AZ 242 is shown in Figure 2b. The geometry of the finaland PPAR, with similar ED50 values of 1.2 M and 1.3
M, respectively. Hence, AZ 242 is an agonist for both model is good, and no outliers have been found in the
Ramachandran plot.PPAR and PPAR.
AZ 242 Cocrystallized with PPAR and -
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Table 1. Data Collection and Refinement Statistics
Diffraction Data
Crystal PPAR/AZ 242 PPAR/AZ 242
Source ID14-4 CuK
Wavelength (A˚) 0.9456 1.542
Space group P3121 C2
Lattice parameters a  b  76.9 A˚, c  100.6 A˚ a  92.9 A˚, b  61.8 A˚,
c  118.9 A˚, and   101.5
Resolution (A˚) 20–2.24 20–2.35
Completeness (%) 99.5 91.3
Rsyma (%) 6.2 6.7
Refinement Statistics
Rworkb (%) 23.7 23.6
Rfreeb (%) 27.1 28.2
Number of Nonhydrogen Atoms Used in Refinement
Protein 2,064 4,134
Heterogen 53 56
Solvent 71 62
Rmsd bonds (A˚) 0.007 0.008
Rmsd angles () 1.2 1.2
Average B factor (A˚2) 48.3 51.5
a Rsym 

hkl
|I(h,k,l,i)  	I(h,k,l)
|

hkl
I(h,k,l,i)
b R 

hkl
||Fobs(h,k,l)|  k|Fcalc(h,k,l)||

hkl
|Fobs(h,k,l)|
Rwork is calculated from a set of reflections in which 5% of the total reflections have been randomly omitted from the refinement and used to
calculate Rfree.
The structure of hPPAR_LBD is very similar to both not interfere with agonist binding in our assays (data
not shown), and its mode of binding is probably specifichPPAR_LBD and hPPAR_LBD (Figure 2c), with an
rmsd between C atoms of only 0.9 A˚ (233 C pairs) to this crystal form.
and 0.8 A˚ (239 C pairs), respectively. A cutoff of 2 A˚
was used in both cases. The domain consists of 12 Ligand Binding Site
The ligand binding site in hPPAR is located in the cen-helices arranged in an antiparallel helix sandwich. In
addition, a 3-stranded antiparallel  sheet is situated in tral core of the LBD, flanked by helices 3, 5, 7, 11, and
12. It is situated in a large T-shaped cavity similar inthe core of hPPAR_LBD. The largest deviation between
the three different crystal structures is found in a region size to that of hPPAR_LBD [9] and hPPAR_LDB [12],
with a volume of about 1300 A˚3. The central cavity spanscomprising residues 231–265, referred to as the omega
loop. This region displays the highest B factors in the domain between the AF2 helix and the 3-stranded
antiparallel  sheet. At the level of the  sheet, the cavityhPPAR_LBD and differs among the various reported
crystal structures of hPPAR_LBD [9, 11]. Residues 449– splits upward and downward along an axis roughly par-
allel to helix 3. These extensions are referred to as the457, preceding the C-terminal helix (helix 12 or AF2 he-
lix), constitute a second region exhibiting a large degree upper and lower distal cavities (Figure 2c).
An apparent entrance to the ligand binding site isof conformational variation between the three subtypes.
This segment is more tightly packed onto the core of the found between helix 3 and the 3-stranded antiparallel
 sheet in a region similar to the proposed entrance indomain in PPAR compared with the other two PPAR
subtypes. hPPAR_LBD and hPPAR_LBD. In the structure pre-
sented here, the region from residue 254 to 264 is notCrystal contacts with a symmetry-related molecule
(symmetry operation: x-y,1-y, 2/3-z) are mediated by included in the model due to poor density. This loop is
highly flexible and partly covers the entrance to thethe steroid part of the detergent molecule (Figure 2a),
explaining the crucial role played by the detergent in ligand binding site. The entrance is further restricted by
Tyr334, which forms a hydrogen bond with Glu282. Thethe crystallization of hPPAR_LBD. The steroid part is
clearly visible in a pocket formed by the N-terminal end equivalent residues to Tyr334 in hPPAR_LBD are
Glu341 in hPPAR_LBD, which appears to be flexibleof  helices 1 and 8 and the C-terminal end of helix 9,
where it forms hydrogen bonds between its axial hy- [9], and Asn307 in hPPAR_LBD. Due to these steric
hindrances, a great deal of flexibility is probably requireddroxyl groups to His411 and Glu451 of the symmetry-
related molecule. This is in contrast to the situation ob- in order for large ligands such as AZ 242 to enter the
ligand binding site. This is supported by the highly flexi-served in hRAR crystals, in which crystal contacts are
formed with a molecule of octyl glucoside occupying ble nature of hPPAR_LBD [14] and hPPAR_LBD, as
observed in our NMR experiments.the coactivator binding site [13]. The DBC molecule did
Structure
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Figure 2. General Structural Features
(a) An overall schematic representation of the hPPAR_LBD structure. The ligand (AZ 242) is shown as a stick model (red). The detergent
(DBC) used for crystallization is represented in cyan. The residues immediately adjacent to the regions excluded from the model are indicated
by their numbers, and helices are labeled H1–H12. The AF2 helix is labeled.
(b) A-weighted Fo-Fc electron density omit map calculated around AZ 242. Residues forming hydrophobic contacts with AZ 242 are represented
in green, and the residue forming the hydrogen bonds with the propionic head group are represented in blue.
(c) A stereo view of a superposition of hPPAR_LBD (red) and hPPAR_LBD (yellow) on hPPAR_LBD (blue). Only the C trace is shown.
Ligands from the three respective structures are shown in green. The central cavity is marked with a “C”, and the upper distal and lower
distal cavities are marked with an “U” and “L”, respectively.
PPAR Agonism Is Caused by a Conserved Hydrogen This situation is also observed with AZ 242 in
hPPAR_LBD. The structure of the AZ 242/ hPPAR_LBDBonding Pattern Involving the AF2 Helix
In all known nuclear receptor crystal structures, the most complex was formed by soaking AZ 242 into crystals of
apo-hPPAR_LBD reproduced from Nolte and collabo-notable structural differences between apo- and ago-
nist-bound LBD are observed in the C-terminal helix rators [9]. The crystal form contains two molecules in
the assymetric unit, denoted A and B, both containingAF2 (e.g., estrogen receptor, PPAR, RAR). The current
model for ligand-dependent activation of nuclear recep- one AZ 242 molecule. The AF2 helix in the A molecule
is in an active state-like conformation, similar to the onetors proposes that agonists stabilize a specific confor-
mation of the AF2 helix. Together with helices 3 and 4, observed for the holo-hPPAR_LBD (PDB accession
code 2PRG [9]) as well as in our AZ 242 hPPAR_LBDthe AF2 helix provides a suitable interface for binding
a coactivator. In our hPPAR_LBD structure, helices 3, structure. The AF2 helix in the B molecule does not
adopt the active conformation despite the presence of4, and AF2 exhibit a conformation similar to that ob-
served in other agonist PPAR_LBD complexes, in accor- the agonist. Unlike in the A molecule, the AF2 helix in
the B molecule forms crystal contacts with a neighboringdance with the agonist nature of AZ 242.
AZ 242 Cocrystallized with PPAR and -
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hPPAR_LBD and hPPAR_LBD also extends to the
coordination of water molecules. A water molecule oc-
cupies the same position, in the vicinity of residue 333
and the distal aromatic ring of AZ 242, in both structures.
A survey of the available PPAR-ligand complexes in the
PDB shows that a water molecule located in this position
is also found in 1GWX (PPAR_LBD in complex with
GW2433), 3GWX (PPAR_LBD in complex with eicosa-
pentanoic acid), and in 2PRG (hPPAR_LBD in complex
with rosiglitazone). Although this water is not involved
in any extensive hydrogen bonding network with the
protein in any of these structures, it is likely to play an
important structural role. These observations support
the crucial role of the hydrogen bonding pattern involv-
ing the four residues mentioned above for ligand binding
and agonist activity in the PPAR family.
A Structural Basis for the Dual Specificity
of AZ 242
PPAR is the molecular target for the thiazolidinedione
class of insulin-sensitizing drugs. Thiazolidinediones
such as troglitazone, pioglitazone, and rosiglitazone se-
lectively bind PPAR, compared with the other two
PPAR subtypes. In contrast, carboxylic acid-based li-
gands such as AZ 242 can activate both PPAR and
PPAR. It appears that most of these differences in
activity can be attributed to the hydrogen bonding head
group. Figure 3b shows a superimposition between the
rosiglitazone-hPPAR and AZ 242-hPPAR hydrogenFigure 3. Structural Explanation for the Dual Affinity of AZ 242 to
PPAR and - bonding patterns. Tyr314 in hPPAR_LBD is bulkier than
its equivalent in both hPPAR_LBD (His321) and(a) Superposition of the ligand binding sites in hPPAR_LBD (blue)
and hPPAR_LBD (green), both occupied with AZ 242. Only residues hPPAR_LBD (His287; not shown in Figure 3b). We sug-
that are involved in hydrogen bonding with AZ 242 are shown. gest that the carboxylate group in AZ 242 is sufficiently
(b) Superposition of the ligand binding site in hPPAR_LBD (blue), small to form a hydrogen bond with the Tyr314O,
occupied by AZ 242, on the ligand binding site in hPPAR_LBD whereas the thiazolidinedione head group is sterically
(green), occupied by rosiglitazone. Only residues that are involved
prevented from forming a similar hydrogen bond.in hydrogen bonding with AZ 242 are shown.
molecule that probably prevent it from moving into the NMR Spectroscopy Shows That the Entire
Structure Is Stabilized by Ligand Bindingactive conformation. We propose that only the A mole-
cule represents a realistic model for the activated NMR spectroscopy is a sensitive probe of protein struc-
ture and mobility. 15N-edited HSQC spectra probing thePPAR protein.
Most known PPAR agonists share features such as a environment of the backbone amide protons can be
used to monitor protein folding and ligand interactions.hydrophilic head group, a central hydrophobic part, and
a flexible linker to the tail. The binding mode of these Figure 4 shows an overlay of the HSQC spectra in the
absence and presence of AZ 242. Several observationscompounds, AZ 242 included, are highly similar, with
the head group interacting with the AF2 helix, the central can be made from a careful comparison of these two
spectra. First, the good dispersion of the crosspeaksring systems forming hydrophobic interactions (Figure
2b), and the tail extending toward the lower or upper and the absence of a high density of resonances around
the random-coil chemical-shift positions in the spec-distal cavity. The hydrogen bond between the AZ 242
carboxylate group and Tyr464 in the AF2 helix in PPAR trum of the apo-LBD shows that it is well folded, with
maybe only a handful of residues in nonstructured re-and - (Figure 3a) is a conserved feature in all agonist
PPAR_LBD complexes and has been proposed to di- gions. Second, a substantial number of crosspeaks
move to a significantly different chemical shift upon li-rectly stabilize the AF2 helix in a conformation that per-
mits coactivator recruitment [10, 12]. The head group of gand addition, indicative of substantial conformational
changes in the protein. The chemical-shift perturbationsAZ 242 is also hydrogen-bonded to Ser280O, Tyr314O
(His321 in PPAR), and His440N2, belonging to helices are much more marked than would be expected if the
ligand merely interacted with some surface residues,3, 5, and 11, respectively, which participate in the coacti-
vator binding site (Figure 3a). This hydrogen bonding hence our conclusion that the protein undergoes a true
conformational change. Third, the HSQC spectrum innetwork is also present in hPPAR_LBD [12] and is
therefore conserved in the entire PPAR family. the presence of a ligand is of higher spectroscopic qual-
ity than the spectrum of the apo protein; the lines areThe overall similarity in the binding mode for
Structure
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Figure 4. NMR Spectroscopy
An overlay of TROSY HSQC spectra of apo hPPAR_LBD (black) and the protein in complex with AZ 242 (red), recorded at 800 MHz.
narrower, and some 10–20 additional crosspeaks can complex with the dihydrocinnamate derivative AZ 242.
be identified. The structure reveals extensive similarities to the other
This indicates that the protein adopts a more rigid and subtypes in the architecture of the ligand binding site.
defined structure, for which we have two explanations. The agonist binding mode exhibits a number of con-
First, the changes may constitute an overall increase in served features throughout the entire PPAR family. Most
the “compactness” of the structure, which decreases of the ligand-protein interactions are hydrophobic, al-
its overall tumbling time and thereby improves cross- though a conserved hydrogen bonding pattern around
peak line widths. Alternatively, the protein in the ab- the hydrophilic head group of the agonist seems to be
sence of ligand may occur partly in multiple conforma- important for activity and specificity. One of the residues
tions, which would lead to line broadening by chemical participating in the hydrogen bonding pattern (Tyr314
exchange, causing spectral degradation. Ligand binding in PPAR) differs between PPAR and -/ and seems
would then force the protein to adopt only a single con- to play a role in ligand specificity. Moreover, a direct
formation. The two explanations are not completely in- hydrogen bond between the AF2 helix and the hydro-
dependent, and both align very well with the common philic head group of the agonist appears to be crucial
understanding that ligand binding to nuclear receptors for maintaining the helix in an adequate conformation
directs helices to adopt a defined position with respect for coactivator recruitment.
to the protein [10, 15]. It is also in line with a recently The NMR data we present here, taken together with
reported observation that ligand binding in the thyroid
the NMR observations on other nuclear receptor ligand
hormone receptor stabilizes the hydrophobic core of its
binding domains, suggest that nuclear receptors areLBD [16]. NMR studies on hPPAR_LBD [14] revealed
quite flexible molecules in the absence of a ligand. Insimilar observations; there, a three-dimensional HNCO
addition, the apo structures of PPAR and PPAR ligandspectrum of the apo protein reveals less than half of the
binding domains suggest that the receptors can adoptresonances of that of the rosiglitazone-bound protein and
the active conformation even in the absence of agonists.even shows multiple peaks for some of the resonances.
All data indicate that the ligand binding domains do notThe authors conclude that the apo hPPAR_LBD is in a
adopt a well-defined structure in the absence of ligands,conformational mobile state, which is frozen into a single
but instead are in a true equilibrium of conformations.conformation by ligand binding. This is similar to our
This indicates a common mechanism of ligand-observations for PPAR.
dependent activation of the PPAR family in which the
ligand acts as a skeleton, enabling the PPAR_LBD bodyConclusions
to interact with molecular partners. Therefore, ligand
binding shifts the protein’s conformational equilibriumWe present the structure of the ligand binding domain
from the third member from the PPAR family, PPAR in to a state that favors coactivator recruitment. This model
AZ 242 Cocrystallized with PPAR and -
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was eluted with a gradient to 100% buffer B supplied with 500 mMalso predicts that coactivator peptides with high affinity
NaCl over 20 column volumes. The protein was then concentrated,to the receptor could bind to the receptor in the absence
desalted against buffer A, and frozen in 2 ml aliquots at a concentra-of any agonist.
tion of 1 mg/ml.
15N labeling of the protein was performed in a medium containing
3/4 M9 minimal medium supplemented with 1/4 Martek 15N-labeledBiological Implications
Celtone. The purification was performed using the same method as
for the nonlabeled protein.The peroxisome proliferator-activated receptors (PPARs)
are nuclear receptors involved in lipid homeostasis. Competition Binding
They have been shown to be activated by fatty acids, A scintillation proximity assay (SPA) was used to determine binding
eicosanoids, as well as antidyslipidemic drugs. The affinities of AZ 242 for hPPAR and mPPAR. The reactions were
performed in 100 l buffer containing 20 mM Tris (pH 7.5), 80 mMthree described subtypes, PPAR, -, and -, have spe-
NaCl, 2 mM TCEP, 0.125% CHAPS, and 10 % glycerol. Each wellcific tissue distributions and are activated by separate
contained 0.1 mg polylysine-coated yttrium silicate beads (Amer-ligands in in vitro test systems. Synthetic, small molecule
sham Pharmacia Biotech), 150 nM PPAR or PPAR, respectively,
ligands have been described for all three receptors, and and 250 nM 3H-AR-H040156 (racemate of AZ 242, 1.12  1015 Bq/
PPAR and PPAR ligands are used clinically as lipid- mol). AZ 242 was added without preincubation. All components
lowering and insulin-sensitizing drugs, respectively. were mixed and incubated while gently shaking for 1 hr at room
temperature. Scintillation counts were determined in a Wallach Tri-The ligand binding domains of the three PPAR sub-
lux (Wallach).types are 60%–65% identical. Given the distinct physio-
logical responses observed for the individual activated
Coactivator Recruitment
receptors, the elucidation of specific ligand-receptor in- The activity of recombinant hPPAR and mPPAR was confirmed
teractions is of great interest. The recently described in a coactivator recruitment assay. Eu3-coupled anti-His antibody
structures for both PPAR and PPAR solved in the (anti-His-Eu3) and APC-coupled streptavidin (SA-APC) were ob-
tained from Wallach. An N-terminally biotinylated 24-amino acidpresence of specific ligands have provided molecular
peptide (Innovagen AB) derived from SRC-1 was used as a coactiva-insights into the binding mode particular for these re-
tor (NH2-CPSSHSSLTERHKILHRLLQEGSPS-COOH). A 45-l reac-ceptors.
tion volume contained 20 mM Tris (pH 7.5), 0.5 M NaCl, 2 mM DTT,
We have performed structural studies on both PPAR 0.05% BSA, 6.8 ng anti-His-Eu3, and 360 ng SA-APC. The PPAR
and PPAR ligand binding domains (LBD) in complex assay contained 800 nM hPPAR_LBD and 1200 nM biotinylated
with AZ 242, a novel dihydro cinnamate derivative ago- SRC-1 peptide; the PPAR assay contained 600 nM mPPAR_LBD
and 800 nM SRC-1 peptide. After the addition of all reagents, platesnist that is structurally different from the thiazolidinedi-
were incubated for 1.5 hr at room temperature, and time-resolvedones and has an affinity for both receptors. NMR spec-
fluorescence was measured in a Victor2 (Wallach). Excitation wastroscopic data obtained from the apo-PPAR and the
at 340 nm, and fluorescence was measured at 620 nm and 665 nm.
AZ 242/PPAR complex show a general stabilization of Specific signals were calculated by dividing the 665 nm signal by
the LBD upon agonist binding. The crystal structures of the 620 nm signal and multiplying the fraction by 10,000.
PPAR and PPAR in complex with AZ 242 reveal a
conserved hydrogen bonding network involving a Tyr in Compounds
The synthesis of the dihydro cinnamate derivative AZ 242 ((S)-2-eth-the AF2 helix that must be formed in order to stabilize
oxy-3-[4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoicthe LBD in the active conformation throughout the entire
acid) was as described (Andersson, K. January 2001. Sweden, pa-PPAR family. A comparison of the ligand binding site
tent WO 9962872). The radiolabeled racemic mixture AR-H040156
allows us to rationalize ligand selectivity toward the  was obtained by reacting an unsaturated precursor with tritium gas.
and  subtypes. Radiochemical purity was 99%, as determined by HPLC.
CrystallizationExperimental Procedures
The protein was concentrated to 7 mg/ml (20 mM Tris, 150 mM
NaCl, 10% glycerol, 1 mM TCEP [pH8]). The ligand AZ 242 wasPurification
added to a final concentration of 0.5 mM, and Deoxy Big CHAPThe ligand binding domains of hPPAR (aa 196–468), hPPAR (193–
(DBC) was added to a concentration of 0.7 mM. The solution was475), and mPPAR (193–475) were expressed as N-terminal His-
mixed to an equal volume of 3.2 M Na Formate, HEPES 100 mMtagged proteins using a pET28a vector (Novagen). The genes were
(pH7.5) and crystallized using hanging drop-vapor diffusion at 293K.cloned between the NdeI and BamHI sites. Freshly transformed E.
Crystals appeared after 7–10 days. Crystals of apo-hPPAR_LBDcoli Bl21DE3 were grown in LB media at 37C to an OD of 0.6. The
were prepared as previously described [9]. Pure AZ 242 was addedculture was induced with 0.1mM IPTG and grown at 18C for 20 hr.
to the crystal in the mother liquor and left to equilibrate for 2–3Cells were harvested and resuspended in a 20 ml/L culture of buffer
weeks.A (20 mM Tris, 150 mM NaCl, 10% glycerol, 1 mM Tris 2-carboxyethyl
phosphine HCL (TCEP, Sigma Aldrich) [pH8]). The cells were dis-
rupted by sonication in the presence of protease inhibitors (Com- Structure Determination and Refinement
Crystals of hPPAR_LBD were transferred into cryoprotectant solu-plete EDTA-free, Roche), and the soluble fraction was isolated by
centrifugation (35,000g, 45 min). The pH of the supernatant was tion (mother liquor  30% v/v glycerol) and immediately thereafter
flash frozen at 100K. The data sets were collected at beam linechecked, and the supernatant was loaded onto Ni-NTA (1 ml/L cul-
ture) and eluted with a gradient imidazole 0–300 mM over 20 column ID14-4 at the ESRF Grenoble on a Quntam4 CCD detector. The
images were indexed and integrated using Mosflm [17] and furthervolumes of buffer A. The fractions containing the protein were dia-
lyzed over buffer A to remove imidazole, and the protein was cleaved processed using SCALA and TRUNCATE from the CCP4 program
package [18] (merging statistics are shown in Table 1). The structurewith thrombin protease (10 U/ mg) at room temperature until comple-
tion, a process that was monitored by ES-MS. The His tag and of hPPAR_LBD was solved by molecular replacement using EPMR
[19]. The structure of apo-hPPAR_LBD [9] was used as a searchuncleaved material were removed by incubation with Ni-NTA. The
flow through was diluted with buffer B (20 mM Tris, 10% glycerol, model. The model of hPPAR_LBD was built using TURBO-FRODO
[20] and refined using simulated annealing and individually re-1 mM TCEP [pH8]) to 20 mM NaCl and immediately loaded onto a Q
sepharose HP column (Amersham-Pharmacia Biotech). The protein strained B factor refinement included in CNX [21]. Both bulk solvent
Structure
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correction and anisotropic B factor scaling were applied. The geom- 12. Xu, H.E., et al., and Milburn, M.V. (1999). Molecular recognition
of fatty acids by peroxisome proliferator-activated receptors.etry of the final model was validated using WHAT-IF CHECK [22].
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